JNJ— Johnson & Johnson
NYSEHealthcare · Drug Manufacturers - General
Johnson & Johnson (JNJ) stock trades at $239.08, up 3.37% on the day. With a market capitalization of $575.52 billion, JNJ is a mega-cap healthcare stock. It trades at a price-to-earnings (P/E) ratio of 27.7, a forward P/E of 18.8 and earnings per share (EPS) of $8.63. Over the most recent period the company reported 10% year-over-year revenue growth and a net profit margin of 21.8%. Below you'll find JNJ's full fundamentals, fair-value estimates, dividend history, earnings and our buy, hold or avoid verdict for 2026.
Price & Performance
Performance
Analysis & Verdict
Johnson & Johnson (JNJ) Stock Analysis 2026
Rule-based · Updated daily · Not financial advice
Johnson & Johnson (JNJ) operates in the Drug Manufacturers - General space within the Healthcare sector. With a market cap of $575.5B, it qualifies as a large-cap company. Growth is moderate and the business remains profitable, offering a balanced risk/reward profile compared to high-multiple peers.
- Forward P/E (18.8×) is lower than trailing P/E (27.7×) — analysts expect earnings to improve
- Revenue growth of 10% YoY shows solid business momentum
- Exceptional profit margin of 21.8% — the business retains a large share of each dollar earned
- ROE of 26.4% shows management efficiently converts equity into profit
- Dividend yield of 2.24% provides consistent income on top of price appreciation
- Low beta of 0.26 — less volatile than the market, suitable for conservative portfolios
- P/E of 27.7× is above average — valuation requires continued strong growth to justify
- Earnings fell 53% YoY — profitability is under pressure
- High debt-to-equity of 67.73× increases financial risk, especially with elevated interest rates
- Price is near its 52-week high — limited near-term upside, higher pullback risk
Verdict
Buy / Hold
More positives than negatives. Fundamentals support holding while monitoring key risks.
AI Insight
Powered by ClaudeAI-generated analysis for informational purposes only. Not financial advice.
Fair Value Estimates
Current price: $239.08
Graham Number
√(22.5 × EPS × Book Value)
$80.94
Benjamin Graham's intrinsic value formula. Assumes a fair stock trades at no more than 22.5× the product of EPS and book value per share.
Bazin Ceiling Price
Avg. Annual DPS (5Y) ÷ 6%
$77.97
Décio Bazin's dividend-based ceiling. The max price you should pay so that dividends alone deliver at least 6% annual yield on your cost basis.
These are simplified estimates. Not financial advice.
Buy & Hold Checklist
Quality criteria for long-term holding
8/10
80% score
Pays dividends
15Y hist.15+ years of dividend history
Dividend consistency (5Y+)
15 yrsUninterrupted dividend payments for at least 5 years
ROE above 10%
26.4%Return on equity — measures how efficiently capital is used
Positive profit margin
21.8%Net profit margin must be positive — company earns more than it spends
Revenue growth (annual)
+9.9%Annual revenue must be growing compared to the prior year
Earnings growth (annual)
-52.9%Annual earnings must be growing compared to the prior year
Debt/Equity below 2×
67.73×Low financial leverage reduces risk of distress
Current ratio above 1
1.02×Short-term assets must cover short-term liabilities
Daily liquidity above $5M
$1.9B/dayHigh trading volume ensures easy entry and exit
Dividend yield above 0%
2.24%Stock must distribute income to shareholders
Financials
Revenue & Results
Key Statistics
Earnings
Next Earnings
Jul 15, 2026
21
days
EPS (TTM)
$8.63
P/E (TTM)
27.7
Fwd P/E
18.8
SEC Filings & Reported Financials
Earnings History
SEC EDGAR · official filings
SEC Filings
Official EDGAR documents
Insider Transactions
SEC Form 4 · officers, directors & 10% owners
Dividends & Income
Dividends
Current DY
2.24%
5Y Avg Annual
$4.3680
Last Payment
$1.3400
Ex-Date
05/26/2026
Annual dividends paid per share
| Ex-Date | Payment | Amount | Est. DY |
|---|---|---|---|
Latest05/26/2026 | 06/09/2026 | $1.3400 | 2.24% |
02/24/2026 | 03/10/2026 | $1.3000 | 2.18% |
11/25/2025 | 12/09/2025 | $1.3000 | 2.18% |
08/26/2025 | 09/09/2025 | $1.3000 | 2.18% |
05/27/2025 | 06/10/2025 | $1.3000 | 2.18% |
02/18/2025 | 03/04/2025 | $1.2400 | 2.07% |
11/26/2024 | 12/10/2024 | $1.2400 | 2.07% |
08/27/2024 | 09/10/2024 | $1.2400 | 2.07% |
Magic Number
Shares needed to self-fund your next purchase
$239.08
Price
$1.3400
Last div. (quarterly)
179
shares
Own 179 JNJ shares ($42,795.32) and each quarterly dividend pays for 1 new share — the snowball runs on its own.
Investment target
$42,795.32
New shares / year
+4 shares
Tools & Simulators
If You Had Invested…
Hypothetical return based on historical prices
* Dividend reinvestment calculated at ex-date price. For informational purposes only.
Discover
Related Assets
Healthcare
Related Articles
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.
Sector
Healthcare
Industry
Drug Manufacturers - General
Location
New Brunswick, United States
Employees
138,200
JNJ — Frequently Asked Questions
Is Johnson & Johnson (JNJ) a good stock to buy in 2026?
Johnson & Johnson (JNJ) shows strengths such as a strong 22% net margin and a 26% return on equity, while risks include high leverage (debt/equity of 67.7). Whether JNJ is a good buy in 2026 depends on your time horizon and risk tolerance — review the full bull case, bear case and fair-value estimates above. This is informational analysis, not financial advice.
What is JNJ's stock price today?
Johnson & Johnson (JNJ) trades at $239.08, up 3.37% on the session. Prices on this page update throughout the trading day.
Does JNJ pay a dividend?
Yes. Johnson & Johnson pays an annual dividend of $5.36 per share, a dividend yield of 2.24%. The most recent ex-dividend date was May 26, 2026. Its payout ratio is about 60% of earnings.
Is JNJ overvalued?
With a P/E ratio of 27.7×, JNJ is valued above the broad-market average for the healthcare sector. Its PEG ratio is 3.01. See the Fair Value Estimates section above for Graham Number and dividend-based price targets.
What is JNJ's market cap?
Johnson & Johnson (JNJ) has a market capitalization of $575.52 billion, classifying it as a mega-cap stock in the Healthcare sector.
Disclaimer: This page — including any buy/hold/avoid view, fair value or price estimate — is generated from market data for informational and educational purposes only and does not constitute financial, investment or trading advice. Data may be delayed or inaccurate. Always do your own research and consult a licensed financial advisor before making any investment decision.